Paclitaxel (Taxol; Bristol-Meyers Squibb Company, New York, New York) is one of a relatively new class of antimicrotubule anticancer agents that belong to the taxane family. A link has been reported between cyclic chemotherapy with paclitaxel and the development of remarkable sclerodermalike changes of the skin.1,2 Although Itoh et al2 reported treating patients with taxane-induced scleroderma, no evidence of immunologic abnormalities was noted, including anticentromere antibodies (ACAs), in any of their patients. Several studies have demonstrated an increased frequency of cancer in patients with systemic sclerosis (SSc), especially lung and breast cancer.3,4 Herein, we describe a Japanese woman who had undergone paclitaxel cyclic chemotherapy for treatment of metastatic breast cancer before presenting with limited cutaneous SSc (LCSSc).
Kawakami T, Tsutsumi Y, Soma Y. Limited Cutaneous Systemic Sclerosis Induced by Paclitaxel in a Patient With Breast Cancer. Arch Dermatol. 2009;145(1):97-98. doi:10.1001/archdermatol.2008.532